In this work we analyzed the cytotoxic effect of BCL2 inhibition by Venetoclax alone or in combination regimen with Nilotinib in primitive and committed CP-CML as well as in Ph+ B-ALL cells. The gene discussed is BCL2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.